SIX · LONN.SW
Lonza Group AG
CHF 640.80+CHF 11.00 (+1.75%)
Lonza Group AG’s quoted price sits in the upper half of its reported 52-week range, 0.12% below the high.
Loading market information…
KSC · 207940.KS · KRW
Stock price, earnings
Quote as of Oct 30, 2026, 02:52 AM UTC. Cached market data; not a live quote.
One-year closing-price history · KRW. Historical prices are not a forecast.
Samsung Biologics Co.,Ltd.’s quoted price sits in the lower half of its reported 52-week range, 28.13% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Samsung Biologics Co.,Ltd.’s next earnings report is currently expected on Jan 27, 2027, with estimated earnings per share of ₩11,137. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Samsung Biologics Co.,Ltd.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Samsung Biologics Co.,Ltd., established in 2011 and headquartered in Incheon, South Korea, provides contract services for biopharmaceutical products. The company's operations are divided into two main segments: Contract Manufacturing Organization (CMO) and Contract Development Organization (CDO). Its CDO services cover areas such as cell line development, optimization of upstream and downstream processes, and the formulation of analytical methods and final products. For CMO, the company offers aseptic filling, lyophilization, finishing, storage, shipping, and various associated support services. Additionally, it delivers comprehensive quality assurance, quality control, biosafety, and analytical testing. Samsung Biologics is also involved in creating and launching biosimilar drugs, alongside manufacturing mammalian cell-based antibody medications.
Latest available per-share figures in KRW. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:12 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q2 2025 | Jul 23, 2025 | ₩4,619-31.79% vs estimate | ₩1.31T-5.35% vs estimate |
|---|
| Q1 2025 | Apr 23, 2025 | ₩5,127+19.93% vs estimate | ₩1.3T+6.95% vs estimate |
|---|
| Q4 2024 | Jan 22, 2025 | ₩4,341+16.03% vs estimate | ₩1.26T+2.02% vs estimate |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
CHF 640.80+CHF 11.00 (+1.75%)
Lonza Group AG’s quoted price sits in the upper half of its reported 52-week range, 0.12% below the high.
CN¥144.15+CN¥1.26 (+0.88%)
WuXi AppTec Co., Ltd.’s quoted price sits in the upper half of its reported 52-week range, 16.96% below the high.
₩190,100+₩800 (+0.42%)
Celltrion, Inc.’s quoted price sits in the lower half of its reported 52-week range, 20.43% below the high.
HK$45.04-HK$0.02 (-0.04%)
WuXi Biologics (Cayman) Inc.’s quoted price sits in the upper half of its reported 52-week range, 22.34% below the high.
HK$67.60-HK$0.30 (-0.44%)
WuXi XDC Cayman Inc’s quoted price sits in the upper half of its reported 52-week range, 21.03% below the high.
HK$37.00-HK$0.70 (-1.86%)
Genscript Biotech Corporation’s quoted price sits in the upper half of its reported 52-week range, 25.19% below the high.
CN¥41.14+CN¥1.14 (+2.85%)
Pharmaron Beijing Co., Ltd.’s quoted price sits in the upper half of its reported 52-week range, 23.2% below the high.
CN¥134.35+CN¥0.14 (+0.1%)
Asymchem Laboratories (Tianjin) Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 32.83% below the high.
